Multimedica S.p.A.

Multimedica S.p.A. conducts research aimed at improving outcomes for patients with cardiovascular disease, including hypertension and heart failure, often in conjunction with respiratory conditions. Trials assess the safety and effectiveness of novel combination therapies and explore how pulmonary treatments impact heart health.

• Hypertension management strategies
• Heart failure and cardiopulmonary outcomes
• Cardiovascular safety of inhaled medications
• Combination therapy to reduce cardiovascular events

The multidisciplinary team collaborates closely with cardiology specialists to ensure patient‑centered care and robust data collection across both heart and lung domains.

The site’s ophthalmology program evaluates innovative treatments for dry eye disease, age‑related macular degeneration, and inflammatory ocular conditions such as atopic keratoconjunctivitis. Studies aim to restore visual function, slow lesion growth, and improve patient‑reported comfort.

• Dry eye disease therapeutic trials
• Geographic atrophy and macular degeneration studies
• Atopic keratoconjunctivitis management
• Polypoidal choroidal vasculopathy interventions

Advanced imaging and patient‑reported outcome measures support the development of next‑generation ocular drugs at Multimedica.

Research at Multimedica also encompasses neoplastic conditions, focusing on the intersection of cancer and systemic health. Trials investigate targeted agents, safety profiles, and the impact of comorbid respiratory disease on cancer therapy effectiveness.

• Targeted therapies for ocular and systemic tumors
• Biomarker studies in cancer patients with lung disease
• Safety evaluation of anti‑angiogenic drugs
• Combination regimens for patients with cardiovascular risk

Collaboration with oncology experts ensures rigorous assessment of novel treatments while prioritizing patient safety.

The core of Multimedica’s clinical research portfolio addresses respiratory tract diseases, including Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, pulmonary arterial hypertension, and progressive fibrosing interstitial lung disease. Trials test inhaled therapies, antifibrotic agents, and combination regimens to improve lung function and quality of life.

• Chronic Obstructive Pulmonary Disease
• Idiopathic Pulmonary Fibrosis and related fibrosing ILDs
• Pulmonary arterial hypertension
• Progressive pulmonary fibrosis
• Nontuberculous mycobacterial lung infection
• Pulmonary sarcoidosis

Long‑term follow‑up studies evaluate safety, tolerability, and functional outcomes, providing valuable insights for patients and clinicians alike.